Global law firm White & Case LLP has advised global growth equity investor Summit Partners on its investment in CluePoints SA, a Belgian fast-growing provider of clinical trial management software.
"This is the latest deal we've advised on that has had a focus on investing in and working with fast-growth businesses, in particular in the tech and biotech sectors," said White & Case partner Ian Bagshaw, who co-led the Firm's deal team.
Founded in 2012, CluePoints is a leader in Risk-Based Quality Management ("RBQM"), offering solutions to pharmaceutical companies and CROs to better identify, visualise, manage and document risks that may impact clinical trials. The company has seen strong growth in recent years, as well as in recent months when the market need has been further accelerated by the COVID-19 crisis.
Founded in 1984, Summit Partners is a global alternative investment firm that is currently managing more than $21 billion in capital dedicated to growth equity, fixed income and public equity opportunities. Its investments include more than 500 companies in healthcare, technology and other growth industries.
Summit will support the company's growth and global expansion to meet accelerating customer demand worldwide.
The White & Case team which advised on the transaction was led by partners Ian Bagshaw and Emmie Jones (both London), and included partners Lindsey Canning and Will Smith (both London), local partner Christophe Goossens (Brussels) and counsel Thomas Glauden (Brussels), with support from associates Helen Pantelides and Elena Ruggiu (both London) and Philippe Hendrickx and Nick Hallemeesch (both Brussels).
For more information, please speak to your local media contact.